IRIDEX Corporation (IRIX)
NASDAQ: IRIXHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IRIX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.92M
- EPS (TTM)
- -$0.19
- Dividend yield
- None
- 52-week range
- 0.4296 – 1.65
- Day range
- 0.4296 – 0.478
- Volume / Avg
- 48.74K / 385.76K
- Beta
- —
- Shares outstanding
- 17.81M
52-week range
IRIX stock today
IRIDEX (IRIX) closed at $0.4449 on Nov 20, down 4.59% (-$0.0214), versus the S&P 500's 3.70% decline. Trading was light, with 48.74K shares changing hands, about 13% of the average daily volume. At this level, IRIX sits near the bottom of its 52-week range of $0.4296 to $1.65: 73.0% below the high, set on Jan 22, 2026 and 3.6% above the low.
IRIX is down 61.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 52.2%. IRIDEX has posted a net loss over the last twelve months (EPS of -$0.19), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About IRIDEX
Company profileIRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CEO
- Mr. Patrick Mercer
- Headquarters
- Mountain View, CA
- Employees
- 93
- IPO year
- 1996
- Website
- iridex.com
Financial highlights
Full financialsIn fiscal 2026, IRIDEX generated $52.7 million in revenue, up 8.2% from fiscal 2024. IRIDEX reported a net loss of $4.4 million, compared with a loss of $8.9 million a year earlier. Gross margin was 36.5% (down from 40.1%) and operating margin -4.9%.
| Fiscal year | FY 2026 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $52.67M | $48.67M | $51.87M | $56.97M | $53.90M |
| Growth | +8.23% | -6.17% | -8.96% | +5.69% | +48.30% |
| Net income | $-4.44M | $-8.91M | $-9.57M | $-7.55M | $-5.22M |
| EPS (diluted) | $-0.26 | $-0.54 | $-0.59 | $-0.47 | $-0.34 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$2.75+518.12%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 17, 2026
- EPS actual vs est.
- $-0.09 vs $-0.04
- Surprise
- -125.00%
IRIX news
All IRIX news- IRIDEX (IRIX) Q3 2026 Earnings Call TranscriptNasdaq
- IRIDEX Corporation Reports Third Quarter 2026 Revenue of $10.2 million and Lowers Full Year GuidanceNasdaqIRIX, SUN
- Iridex Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Iridex to Report Third Quarter 2026 Financial Results on November 17, 2026GlobeNewswire
- Iridex Reports Sustained Glaucoma Benefits With MicroPulse Laser Therapy At Two YearsNasdaqIRIX, ET
- Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced GlaucomaGlobeNewswire
IRIDEX peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NDRAENDRA Life Sciences Inc. | 3.58 | -3.38% | $5.36M | vs IRIX |
| ITOCiTonic Holdings Ltd Class A | 1.59 | +6.00% | $11.63M | vs IRIX |
| NUWENuwellis Inc. | 3.41 | -10.50% | $1.84M | vs IRIX |
| NXLNexalin Technology Inc. | 1.38 | -2.13% | $1.71M | vs IRIX |
| VBIOValion Bio Inc. | 0.4806 | -10.98% | $1.04M | vs IRIX |
| QTIQT Imaging Holdings Inc. | 1.92 | +2.67% | $28.21M | vs IRIX |
| ECORelectroCore Inc. | 4.42 | -8.87% | $40.78M | vs IRIX |
| POCIPrecision Optics Corporation Inc. | 4.12 | +1.41% | $45.30M | vs IRIX |
Indexes, lists and sector
IRIDEX stock FAQ
What is IRIDEX's stock price today?
IRIX last traded at $0.4449 as of Nov 20, 4:00 PM EST, down 4.59% on the day. Prices are delayed at least 15 minutes.
Who is IRIDEX's CEO?
Mr. Patrick Mercer is the chief executive officer of IRIDEX Corporation, which has about 93 employees.
What is the IRIX 52-week high?
The 52-week high for IRIX is $1.65 and the 52-week low is $0.4296. The stock is currently 73.0% below its high.